Our case further extends this paradigm by adding a homozygous MTHFR mutation, thus representing a rare triad that has likely amplified both thrombotic and obstetrical risks beyond those observed in isolated APS or single-gene thrombophilia carriers. This evidence concerns the gene MTHFR and autoimmune polyendocrinopathy.